Advancing Cancer Treatment Through Research & Innovation
Our research focuses on developing breakthrough treatments that combine cutting-edge science with personalized patient care, pushing the boundaries of what's possible in cancer treatment.
Current Research Projects
Our current research projects are focused on developing breakthrough treatments that combine cutting-edge science with personalized patient care, pushing the boundaries of what's possible in cancer treatment.
Efficacy of Compression Therapy for Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients with Early Breast Cancer: Insights from a Single-Centre Experience in Bangladesh
Prospective
Research Objectives:
- • Incidence of CTCAE version 5 grade 2 or higher CIPN in both upper and lower extremities during entire period of chemotherapy.
The Efficacy of Pembrolizumab for Treatment of Early Triple Negative Breast Cancer: A Single-center, Open, Randomized Controlled Trial
Primary endpoints: A) Pathological Complete Response at the time of definitive surgery B) Event-free survival in the intention-to-treat population Secondary endpoints: Overall survival at the end of 15 months
Research Objectives:
- • A prospective study to measure the efficacy of Pembrolizumab in Early Triple Negative Breast Cancer (TNBC) patients of Bangladeshi population.
Recent Publications
Peer-reviewed research contributions published in leading oncology journals, advancing the field of cancer treatment.
Genomic Alterations in Advanced Lung Cancer Patients Compared via CGP and Hotspot Panel Test in a Bangladeshi Tertiary Hospital
In this retrospective observational study, the preliminary data were collected from hospital information system containing 4435 oncology OPD cases. Genomic alteration data were collected from test reports of 62 advanced …
Key Findings:
Among 4435 oncology OPD cases, 760 (17.1%) cases were of primary lung cancer, and 76% were presented in stage III-IV. CGP identified more actionable genomic …
Childhood Sacrococcygeal Teratoma: A Histopathological Study
The study included 66 patients of SCT operated from 2015 to 2021. A retrospective review of different clinical information and histopathological findings was done from the radiological and pathological records …
Key Findings:
There were 44 females and 22 males with age ranging from newborn to 08 years. Forty two children (63%) presented in the neonatal age group. …
Pattern of Practices of Oncologists of Bangladesh in the COVID-19 Era
This was a cross-sectional survey-type study, based on a questionnaire, which was shared via email to national oncologists and enhanced by snowballing in April–May 2020.
Key Findings:
A total of 48 responders joined the survey, mostly clinical and radiation oncologists practicing in specialized cancer centers of the major cities. Patients’ triage for …
Showing 7 to 9 of 19 publications
Conference Presentations & Speaking Engagements
Sharing research findings and clinical insights at leading medical conferences worldwide.
15TH EUROPEAN BREAST CANCER CONFERENCE
The Impact of Dual vs Single Anti-HER2: A Real-World Retrospective Analysis of Treatment Outcome in Bangladesh
Background The integration of dual HER2 blockade (trastuzumab + pertuzumab, PH) has improved outcomes in HER2-positive breast cancer, particularly in neoadjuvant and metastatic settings. However, evidence from routine clinical practice in low- and middle-income countries is limited. This study aimed to evaluate real-world survival outcomes, response rates, and safety of dual versus single blockade (trastuzumab alone, H) across treatment settings.
ISRS 2026
FRACTIONATED STEREOTACTIC RADIOTHERAPY (FSRT) FOR OLIGOMETASTATIC DISEASE: A SINGLE-CENTER EXPERIENCE FROM BANGLADESH
Background: Oligometastatic disease represents a biologically intermediate state where aggressive metastasis-directed therapy may improve durable disease control. Fractionated stereotactic radiotherapy (FSRT)enables safe delivery of ablative doses to intracranial and extracranial lesions. We report updatedoutcomes of linac-based FSRT with the inclusion of an additional patient.
40th The Society for Immunotherapy of Cancer (SITC) 2025
The Role of Concomitent MET Amplification and High PD-L1 Expression in Non-Small Cell Lung Cancer: A case report of Implications for Targeted Therapy and Immunotherapy
MET amplification occurs in approximately 1-5% of treatment-naïve non- small cell lung cancer (NSCLC) cases. It can also develop as an acquired resistance mechanism, particularly after treatment with EGFR tyrosine kinase inhibitors (TKIs), where it's observed in about 15% of cases. This case underscores the coexistence of MET gene amplification and high PD-L1 expression in NSCLC, which has significant therapeutic implications. The presence of MET amplification suggests potential benefit from MET- targeted therapies, while high PD-L1 expression indicates responsiveness to immune checkpoint inhibitors. When MET amplification and high PD-L1 co-exist, the optimal treatment strategy can be challenging. The integration of molecular and immunohistochemical data guides personalized treatment strategies for this patient.
40th The Society for Immunotherapy of Cancer (SITC) 2025
Pathological complete response with Pembrolizumab in combination with chemotherapy for Neoadjuvant Treatment of Early Triple Negative Breast Cancer: A Single-center prospective study from Bangladesh.
Triple negative breast cancer is the kind of breast cancer that does not have any receptors which are usually found in breast cancer. It is estrogen- receptor, progesterone-receptor, and HER-2 receptor negative. About 10-15% of all breast cancers are triple negative. Its commonly seen in women aged than 40 years, and those have a BRCA-1 mutation. This is a more aggressive form of cancer, harder to treat and has chances of recurrences. The single most prognostic factor is still the pathological complete response in case of neoadjuvant (NACT)settings.
Showing 1 to 4 of 8 presentations